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BACKGROUND: Ovarian cancer is the most lethal gynaecological malignancy. Although ovarian cancer patients often respond initially to
chemotherapy, they usually develop chemoresistance. We hypothesised that a small portion of ovarian cancer cells have stem-like cell
properties that contribute to tumourigenesis and drug resistance.
METHODS: Flow cytometry and Hoechst 33342 efflux isolated side-population (SP) cells from ascites derived from ovarian cancer
patients and from mice inoculated with human ovarian cancer cell lines. The SP cells were examined for stem cell markers OCT4,
NANOG, STELLAR, and ABCG2/BCRP1 by immunocytochemistry and RT–PCR. The SP cells and non-SP cells were studied for
tumourigenesis and chemoresistance in vitro and in vivo.
RESULTS: The SP cells expressed ABCG2/BCRP1, OCT4, STELLAR, and NANOG, detected by immunocytochemistry and RT–PCR.
ABCG2/BCRP1 expression was higher in SP than in non-SP cells. Xenogeneic mice inoculated with SP cells yielded more tumours
than did mice inoculated with non-SP cells. In parallel, SP cell culture resulted in extensive cell proliferation, which was markedly more
than in non-SP cells. SP cells resisted chemotherapy compared with non-SP cells, both in vivo and in vitro.
CONCLUSION: Ovarian cancer SP cells are tumourigenic and chemoresistant. ABCG2/BCRP1 has an important role in
chemoresistance, which has implications for new therapeutic approaches.
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The majority of ovarian cancer patients with advanced disease
eventually develop chemotherapy resistance. The concept of
cancer stem-like cells in solid tumours opens new approaches to
carcinogenesis and chemotherapy. Cancer stem-like cells share
many properties with normal stem cells: they have a protracted
lifespan, relative quiescence, ability for self-renewal, the capacity to
induce tumourigenesis, and resistance to chemotherapeutic agents
and apoptosis (Reya et al, 2001; Beachy et al, 2004; Sales et al,
2007; Wu et al, 2007).
Surface markers expressed on cancer stem-like cells can be used
to isolate these cells. However, these markers differ in different
types of tumours. The capacity to extrude Hoechst dye, one of the
stem cell characteristics, has also been used to identify cancer
stem-like cells (Dean et al, 2005). These cells express drug
transporters that make them resistant to many chemotherapeutic
agents (Allikmets et al, 1998a; Dean et al, 2005). ABCG2/BCRP1
(breast cancer-resistance protein-1), an ATP-binding cassette
(ABC) transporter, is a cell surface drug-resistance marker as
well, which has been used to identify stem cells from a variety of
tissues, including tumours (Zhou et al, 2001b; Diestra et al, 2002a).
ABCG2/BCRP1 expression confers resistance to chemotherapeutic
agents and permits cells to exclude Hoechst dye 33342 (Molecular
Probes, Eugene, OR, USA) (Allikmets et al, 1998a; Dean et al,
2005). This dye-excluding side-population (SP) phenotype has
been used in various tissues to select presumptive stem-like cells.
Side-population cells are enriched with cancer stem-like cells in a
variety of carcinomas (Kondo et al, 2004a; Hirschmann-Jax et al,
2005; Haraguchi et al, 2006; Ho et al, 2007; Wang et al, 2007).
These cells have been found in several tissues and cell lines,
including bone marrow, skin, lung, mammary epithelium, and
embryonic stem cells (Alvi et al, 2003; Nishimura et al, 2003;
Majka et al, 2005; Yano et al, 2005). They have been isolated from
malignancies, including leukaemia (Feuring-Buske and Hogge,
2001; Wulf et al, 2001) and breast (Doyle and Ross, 2003), brain
(Hirschmann-Jax et al, 2005), prostate (Hirschmann-Jax et al,
2005), retinoblastoma (Seigel et al, 2005), lung (Giangreco et al,
2004), and ovarian (Patrawala et al, 2005; Szotek et al, 2006)
cancers.
The SP phenotype, coupled with the expression of stem cell
markers, is the hallmark of normal stem cells and cancer stem-like
cells as well (Zhou et al, 2001b; Scharenberg et al, 2002; Diestra
et al, 2002a; Dean et al, 2005).
We explored the tenet that SP cells isolated from human ovarian
cancer cells by Hoechst dye exclusion after flow cytometry
show stem cell characteristics. The SP cells were examined for
the drug-resistance transporter, ABCG2/BCRP1, and for other stem
cell markers, OCT4, NANOG, and STELLAR, by immunocyto-
chemistry and RT–PCR. The SP and non-SP cells were studied for
tumourigenesis and chemoresistance in vitro and in vivo.
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Materials
The ABCG2/BCRP1 monoclonal antibody (BXP-21) was from
Sigma Chemicals (St Louis, MO, USA). The OCT 4 monoclonal
antibody was from Chemicon (Tarrytown, NY, USA). NANOG and
STELLAR polyclonal antibodies were kindly provided by Dr A.
Clark (University of California, San Francisco (UCSF)). Cisplatin
was from Sigma Aldrich (St Louis, MO, USA). The human
OVCAR3 cell line was a gift from Dr T. Hamilton (Fox Chase
Cancer Center, Philadelphia, PA, USA), and the ovarian cancer
cisplatin-resistant cell line, A2780-CP, was a gift from Dr J. Chan
(UCSF). All other cell lines were from the UCSF Gynecologic
Ovarian Tissue Bank. Culture reagents were obtained from the Cell
Culture Facility, UCSF.
Human ovarian cancer ascites
Primary ovarian cancer cells were collected from stage III fresh
ovarian cancer patient ascites at laparotomy through the UCSF
Gynecologic Ovarian Tissue Bank. Ascite fluid was collected and
was placed in a refrigerator at 41C for 1–2h. After discarding the
supernatant, cells were resuspended in medium (RPMI-1640) and
centrifuged to isolate the cellular components. The cells were then
cultured with medium RPMI-1640 supplemented with 2.0gl
–1
glucose and 0.3gl
–1 L-glutamine, as well as with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin, and 1% fungizone and
incubated at 371C. Cells were analysed within 7 days, during which
sorting of SP cells by flow cytometry, RT–PCR, and immunoassay
was performed.
Experimental animals
Female athymic immunodeficient mice (Simonsen Laboratories,
Gilroy, CA, USA) were delivered to the UCSF Laboratory Animal
Resource Center, and were housed in isolated conditions, fed
autoclaved standard pellets and water, and allowed to adapt to
their new environment. All protocols involving immunodeficient
mice were approved by the Committee on Animal Research, UCSF.
Mouse ovarian cancer ascites
Mouse ascites were collected from female athymic nude mice (5–7
weeks old) inoculated i.p. with human OVCAR3 cells for 6 weeks.
Cells were analysed within 7 days with sorting of SP cells by flow
cytometry, and RT–PCR and immunoassay were performed as
described in the human ovarian cancer ascites section.
Identification of SP cells
Identification of SP cells was performed as described previously by
Goodell (2002). Cells were incubated with 5mgml
–1Hoechst 33342
dye (Molecular Probes) for 90min with and without 50mM
verapamil. Cell samples were analysed and sorted using a Moflo
MLS cell sorter (Beckman-Coulter, Inc., Hialeah, FL, USA) with UV
capabilities and SUMMIT software for data acquisition and
analysis. An argon laser was used to excite the Hoechst dye.
Fluorescence emission was collected with a 405/30nm bandpass
filter for Hoechst blue and a 670/40nm bandpass filter for Hoechst
red. Dead cells were excluded by propidium iodide fluorescence at
670/30nm.
Kidney capsule graft
Side population cells or non-SP cells (500 cells each) were isolated
from ascites derived from mice inoculated with the human ovarian
cancer cell line, OVCAR3, or from ascites derived from ovarian
cancer patients, suspended in 50ml of rat tail collagen gel as
previously described (Hayward et al, 2001) and grafted under the
kidney capsule of female athymic mouse hosts. The hosts were
killed after 8 weeks of growth and the kidneys with grafts were
explanted, fixed in formalin, and embedded in paraffin.
Intraperitoneal inoculation of SP cells
Two groups of nude mice (n¼12) were inoculated separately i.p.
with SP cells vs non-SP cells (20000 cells each) from A2780-CP
(cisplatin-resistant human ovarian cancer cell line). At 8 weeks
after inoculation, the mice were killed and tumour burden was
quantified. In a separate experiment, four groups of nude mice
(5–7 weeks old, n¼16) were inoculated i.p. with SP vs non-SP
cells (20000 cells) from A2780-CP. At 2 weeks after inoculation,
two groups (SP (n¼4) vs non-SP cells (n¼4)) were treated
with cisplatin (10mgkg
–1 B.W.) 3 times weekly for 3 weeks. Two
additional groups (SP (n¼4) vs non-SP cells (n¼4)) received
vehicle alone.
SP culture Side population cells and non-SP live cells (500 cells
each) obtained from ascites derived from ovarian cancer patients
were seeded on 24-well plastic culture plates. Cells were cultured in
RPMI-1640 containing 10% FBS, 100unitsml
–1 penicillin, and
100mgml
–1 streptomycin. Cultures were incubated at 371Ci na
humidified atmosphere of 95% O2 and 5% CO2. The medium was
changed every other day. The morphological appearance of
cells was captured at the end of the fifth day of culture. At least
ten  150 microscopic fields were scored.
Reverse transcription–polymerase chain reaction (RT–PCR)
Total RNA was extracted from pellets of human ovarian cancer
cells from ascites derived from patients and mice bearing human
OVCAR3 cells using an RNeasy minikit (Qiagen, Hiden, Germany)
according to the manufacturer’s protocol. Reverse transcription–
polymerase chain reaction was then performed using a OneStep
RT–PCR Kit (Qiagen). The primers used for PCR amplification
were BCRP1 (231bp): 50-CAACCATTGCATCTTGGCTG-30 and 50-CA
AGGCCACGTGATTCTTCC-30; STELLAR (174bp): 50-GTTACTGGG
CGGAGTTCGTA-30 and 50-TGAAGTGGCTTGGTGTCTTG-30.C o n d i -
tions for both BCRP1 and STELLAR were 951Cf o r1m i n ,5 81Cf o r
1min,and721C for 2min, for 40 cycles. Acquired DNA samples were
loaded onto a 2% agarose gel and analysed.
Fluorescent immunostaining in suspension Patient ovarian
cancer cells or OVCAR3 cells were double labelled in suspension
with Hoechst 33342, and with either ABCG2/BCRP1 or OCT4. Cells
(2 10
6) were centrifuged at 800r.p.m. for 5min. The supernatant
was decanted and cells were resuspended in 4ml RPMI with 10%
fetal calf serum. Hoechst 33342 dye (Molecular Probes) was added
at 5mgml
–1, and cells were incubated at 371C for 90min. Cells
were washed twice in PBS and centrifuged for 5min. Cells were
resuspended in PBS and then received 1:200 ABCG2/BCRP1
antibody or OCT 4 antibody and were incubated for 1h at room
temperature. Cells were washed twice with PBS and resuspended.
TRITC-conjugated anti-mouse IgG (Sigma Chemicals) was added
at 1:100 dilution. Cells were incubated for 1h at room
temperature. After washing twice with PBS, cells were resuspended
and pipetted onto a slide and covered with a coverslip for
microscopic viewing.
Immunofluorescent analysis of SP cells Side population cells were
sorted directly onto poly-L-lysine-coated slides, then air-dried and
fixed in 50:50 methanol/acetone for 5min as described by Alvi
et al (2003). The cells were pretreated with 3% horse serum in
PBS plus 0.05% Tween-20 for 1h, and then rinsed in PBS and
incubated with both 1:500 rabbit anti-NANOG antibody and
1:200 mouse anti-ABCG2/BCRP1 antibody for 1h. The cells were
thoroughly washed in PBS before application of 1:200 of both
Ovarian cancer side population is tumourigenic and drug resistant
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mouse IgG, and finally washed again in PBS. A similar procedure
was used for staining CD34 1:200 with mouse anti-CD34 antibody
and for staining CD44 1:200 with mouse anti-CD44 antibody.
Immunofluorescence in tumour tissues The ovarian cancer tissue
from mice inoculated with OVCAR3 cells was washed extensively
in PBS. Before immunostaining, tissues were pretreated with 3%
horse serum in PBS plus 0.05% Tween-20 for 1h. Tissues were
rinsed in PBS and incubated with both 1:500 rabbit anti-NANOG
antibody and 1:200 mouse anti-ABCG2/BCRP1 antibody for 16h
on an orbital shaker at 41C. Tissues were washed thoroughly in
PBS before application of 1:200 of both FITC-conjugated anti-
rabbit IgG and TRITC-conjugated anti-mouse IgG, and finally
washed again in PBS. Immunostained tissues were examined by
microscopy.
Apoptosis assessment Side population cells vs non-SP cells were
seeded (5000 cells) on eight-well glass culture slides. Cells were
cultured in RPMI-1640 for 24h. The medium was then removed
and replaced with culture medium in four individual wells for SP
cells vs non-SP cells: (1) vehicle, (2) cisplatin 5mM, (3) verapamil
50mM, and (4) cisplatin plus verapamil, for an additional 48h.
After fixing with 2% paraformaldehyde, cells were used to assess
apoptosis. DNA labelling with digoxigenin dUTP and terminal
transferase, followed by immunocytochemical staining with
peroxidase-coupled antidigoxigenin antibody and diaminobenzi-
dine, was carried out with the reagents supplied in the Apoptag kit
(Intergen, Purchase, NY, USA). After light counterstaining with
haematoxylin, nuclei that stained brown were scored as positive
for apoptosis and those that stained blue were scored as negative.
At least ten  150 microscopic fields were scored, and the
apoptotic index was calculated as the percentage of cells that were
scored positive.
Light microscopy and analysis Ovarian cancer tissue and cells
immunostained with ABCG2/BCRP1, OCT4, and NANOG were
examined with a Leica DMRB or Leica (Allendale, NJ, USA)
Ortholux II photomicroscope at low and high magnification.Images
were collected with a Photonics (Fukuoka, Japan) DEI-470 CCD
camera and a RasterOps (Santa Clara, CA, USA) 24X LTV frame
grabber, imported directly into Adobe Photoshop (San Jose, CA,
USA). Photomicrographic plates were composed from the original
data in Photoshop without alteration or manipulation.
Statistics Data were analysed using the unpaired Student’s t-test
for comparison between groups. Differences between groups were
considered statistically significant at Po0.05. Experiments in vivo
were performed in duplicate, whereas experiments in vitro were
performed in triplicate.
RESULTS
Ovarian cancer SP cells
Figure 1 shows two representative experiments from flow
cytometry. Panel A shows a small number of cells (1.65%) in the
box R4 from the SP from OVCAR3 cells. The SP was blocked by
88% by 50mM verapamil. Panel B illustrates a small number of cells
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Figure 1 (A) Side population (SP) of human OVCAR3 ovarian cancer cells from mouse ascites detected by flow cytometry. Boxed cells (labelled R4)
indicate Hoechst-excluding SP. (B) SP of patient ascites-derived ovarian cancer cells detected by flow cytometry. Boxed cells (labelled P3) indicate Hoechst-
excluding SP. Addition of 50mM verapamil resulted in a marked reduction in SP in A and B.
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The SP was blocked 80% by 50mM verapamil.
The mean percentage of SP cells from ascites derived from
human ovarian cancer patients, ascites from mice inoculated with
OVCAR3, and A2780-CP cell lines were 0.4±0.05%, 1.01±0.27%,
and 0.45±0.05%, respectively. We also sorted SP cells from other
human ovarian cancer cell lines, including A2780, HEYA8, OCC1,
and SKOV3. Percentages from these cell lines ranged from 0.1 to
2.4%, (A2780: 0.2%; HEYA8: 2.4%; OCC1: 0.1%; and SKOV3: 1.7%).
OCT4 and ABCG2/BCRP1 immunopositive cells colocalise
with Hoechst-dim cells in OVCAR3 cells
Staining of OCT4-immunopositive OVCAR3 cells was detected
in Hoechst-dim cells, further suggesting a stem cell phenotype
(Figure 2A–D). OVCAR3 cells that were Hoechst-dim (Figure 2B)
were OCT4-bright (Figure 2C), as seen more definitively in the
merged image (Figure 2D). Bright-field images were captured
(Figure 2A) to ensure that labelled cells appeared intact.
Figure 2E–H shows that ABCG2/BCRP1 confers the ability to
exclude Hoechst dye. OVCAR3 cells immunoreactive for ABCG2/
BCRP1 were Hoechst-dim (Figure 2F and G). OVCAR3 cells that
were ABCG2/BCRP1-bright were Hoechst-dim, as seen in the
merged image (Figure 2H). Bright-field images were captured
(Figure 2E). These findings show that ABCG2/BCRP1 colocalises
with Hoechst-dim cells.
Immunoreactivity of stem cell markers in sub-populations
of OVCAR3 cells
The SP phenotype is thought to occur through action of the
ABCG2/BCRP1 transport cassette protein (Zhou et al, 2001a;
Ahmed-Belkacem et al, 2006). To analyse whether SP cells
coexpressed stem cell markers ABCG2/BCRP1 and NANOG, we
examined their immunological activity. We found that SP cells
stained strongly with ABCG2/BCRP1 antibody (Figure 2I), and that
SP cells also costained with NANOG (Figure 2K), as seen
particularly in the merged image (Figure 2L). Bright-field images
were captured in Figure 2J. In contrast, SP cells were not stained by
CD34, a haematopoietic stem cell marker (data not shown),
suggesting that the preparations were not contaminated with
haematopoietic stem cells. The SP cells were not stained
significantly by CD44 either (data not shown).
Cancer stem cell niche
Figure 2M–P shows the cancer stem-like cell niches in the tumour
tissue. These cells share the SP phenotype and are costained with
ABCG2 and NANOG, as shown in Figure 2I–L. Figure 2M shows
that cells stained strongly with the ABCG2/BCRP1 antibody and
also costained with NANOG (Figure 2O), as seen particularly in the
merged image (Figure 2P). Bright-field images are seen in
Figure 2N.
Chemoresistance and apoptosis
Figure 2Q–T illustrates apoptosis of cultured SP cells from A2780-
CP after 48h of treatment with cisplatin and/or verapamil in vitro.
Apoptosis in SP cells in the cisplatin-treated group was o20%,
indicating that SP cells were resistant to chemotherapy. However,
over 95% of SP cells in the cisplatin plus verapamil-treated group
were apoptotic. There were no significant apoptotic cells in control
SP and verapamil-treated SP cells. The brown nuclei and debris
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Figure 2 (A–D) Colocalisation of cells from mouse ascites bearing human ovarian cancer cells with OCT4 and Hoechst dye 33342. (E–H)
Colocalisation of cells from mouse ascites bearing human ovarian cancer cells with ABCG2/BCRP1 and Hoechst dye 33342. (A, E) Bright-field; (B, F)
Hoechst-dye uptake (blue); (C) OCT4 (bronze); (G) ABCG2/BCRP1 (bronze); (D) merged image B and C; and (H) merged image F and G. Arrows
indicate the cells that are immunoreactive for OCT4 or ABCG2 and Hoechst-dim. Bar ¼10mm. (I–L) Immunolocalisation of ABCG2/BCRP1 (red
fluorescence) and NANOG (green fluorescence) in side population of human ovarian cancer cells (OVCAR3) derived from mouse ascites. (I) ABCG2/
BCRP1; (J) bright-field; (K) NANOG; (L) merged I and J. Bar ¼10mm. (M–P) Immunolocalisation of ABCG2/BCRP1 (red fluorescence) and NANOG
(green fluorescence) in mouse cancer tissues bearing human ovarian cancer cells. (M) ABCG2/BCRP1; (N) bright-field; (O) NANOG; and (P) merged M
and O. Arrows indicate cells that are immunoreactive for OCT4 or ABCG2. Bar ¼10mm. (Q–X)S Pvs non-SP cell apoptosis in vitro. Apoptosis of SP (Q–
T) vs non-SP cells (U–X) after 48-h treatment with cisplatin and/or verapamil in vitro.( Q, U) Control; (R, V) cisplatin; (S, W) verapamil; and (T, W)
cisplatin plus verapamil. Brown nuclei indicate apoptotic cells. Scale bar¼10mm. Note that SP cells are resistant to cisplatin (R), but this resistance is
reversed by verapamil (T).
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microscopic fields were scored.
In a parallel study, we also showed apoptosis in cultured non-SP
cells in Figure 2U–X. Apoptosis of non-SP cells in both the
cisplatin-treated group and cisplatin plus verapamil-treated group
was over 90% of the total cell population. However, there were no
significant changes in the control and verapamil-treated groups.
Gene expression
Reverse transcriptase–PCR revealed that ABCG2/BCRP1 and
STELLAR mRNA expressions were found in both human
embryonic stem cells and OVCAR3 cells (Figure 3A). Because
ABCG2/BCRP1, a drug-resistance transporter, is a key molecule in
SP cells, ABCG2/BCRP1 mRNA was analysed in both sorted SP and
non-SP cells. ABCG2/BCRP1 was expressed in SP cells more
extensively than in non-SP cells (Figure 3B). ABCG2/BCRP1
expression was also found in human ovarian cancer cells from
patient ascites (Figure 3C) and was expressed in SP cells more
extensively than in non-SP cells.
SP and tumourigenesis
Figure 4A and B shows non-SP and SP live cells obtained from
patient ovarian cancer ascites and cultured for 5 days. SP cells
(Figure 4B) have high-density chromatin and undergo extensive
proliferation (Figure 4A), whereas non-SP (Figure 4B) cells do not
proliferate significantly.
Figure 4D shows tumour growth from SP cells derived from
patient ovarian cancer ascites and grafted under the kidney
capsule. In contrast, tumours did not develop in non-SP cells
grafted under the kidney capsule (Figure 4C). Figure 4F illustrates
tumour growth from the SP cells derived from mice inoculated
with OVCAR3 cells and grafted under the kidney capsule. In
contrast, tumours did not develop in non-SP cells similarly grafted
(Figure 4E).
Figure 4G and H shows tumour burden in mice after 8 weeks
of inoculation with non-SP or SP cells from the A2780-CP cell
line injected i.p. (three representative mice in each group). Note
the extensive tumourigenesis in SP-inoculated mice compared
with non-SP cell-inoculated mice. The mean tumour burden in
SP-inoculated mice (7.29±0.73) was significantly (Po0.0001)
greater (93.85%) than that in non-SP-inoculated mice (0.44±0.12).
Chemoresistance in the mouse model
The effects of cisplatin on tumour growth in nude mice (n¼16)
are shown in Figure 5. Treatments began 2 weeks after the mice
were inoculated with SP vs non-SP from A2780CP cells. Tumour
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Figure 3 (A) RT–PCR analysis of ABCG2 and STELLAR in mouse
ascites from human ovarian cancer (OVCAR3) and human embryonic stem
cells (hESCs). (B) RT–PCR analysis of ABCG2 in non-SP and SP from
human ovarian cancer cells (OVCAR3). (C) RT–PCR analysis of ABCG2 in
non-SP and SP cells from human ovarian cancer cells (hOCCs).
NSP
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SP NSP
NSP SP
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Figure 4 Non-SP cells (A) vs SP cells (B) from patient’s ovarian cancer
ascites were cultured for 5 days. Non-SP cells (C) and SP cells (D) from
human ovarian cancer cells (500 cells) derived from patient’s ascites were
grafted under kidney capsules in each of two mice for 8 weeks. Non-SP
cells (E) and SP cells (F) from OVCAR3 cells (500 cells) derived from
mouse model ascites were grafted under kidney capsules in each of two
mice for 8 weeks. Non-SP cells (G, three mice) and SP cells (H, three
mice) from A2780-CP (cisplatin resistant) cells were injected i.p. into six
mice (20000 cells per mouse) for 8 weeks. Bar¼10mm.
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sburden in SP cisplatin-treated mice (6.920±1.226g) was not signi-
ficantly reduced (23.08%) compared with that in SP control mice
(8.997±1.297g), indicating that SP cells are resistant to chemo-
therapy. Tumour burden in cisplatin-treated mice (0.0325±
0.018g) inoculated with non-SP cells was reduced by 94.9%
(Po0.05) compared with that in non-SP-inoculated control mice
(0.6426±0.23g). Regarding the differences in tumour burdens
between SP- and non-SP-inoculated mice, tumour burden in SP
control mice was greater (92.3%) than that in the non-SP control
group.
DISCUSSION
In this study, we show that SP cells have an important role in
tumourigenesis and drug resistance in human ovarian cancer, both
in vivo and in vitro. We identified a small SP population from
ovarian cancer cells derived from ascites from patients and from
nude mice inoculated with the human OVCAR3 cell line, as well as
from other human ovarian cancer cell lines, including A2780,
A2780-CP, HEYA8, OCC1, and SKOV3. This is consistent with
findings in other tumour types (Patrawala et al, 2005; Szotek et al,
2006).
Our study indicates that ovarian cancer cells are heterogeneous.
SP cells are highly proliferative compared with non-SP cells; SP
xenogeneic transplant mice grew more tumours than non-SP
xenogeneic transplant mice, as shown from other studies (Chiba
et al, 2008; Harris et al, 2008; Steiniger et al, 2008). SP cells have
characteristics of cancer stem-like cells. They have a striking
capacity to proliferate, differentiate, and undergo self-renewal,
enabling them to eventuate in tumour formation and repopulate
tumours after therapy (Alvi et al, 2003; Kondo et al, 2004b;
Hirschmann-Jax et al, 2005). This small population is likely to be
responsible for tumourigenesis. Although current chemotherapy
for ovarian cancer eradicates most tumour cells with high initial
response rates, the majority of patients with advanced disease
eventually become resistant to chemotherapy. This raises the
possibility that failure to eradicate ovarian cancers may be because
of failure to treat the definitive target: cancer stem-like cells. Both
our in vitro and in vivo experiments show that SP cells are resistant
to chemotherapy. This novel finding suggests that SP cells
contribute to drug resistance and might be an attractive target
for cancer therapy.
Our study shows that ovarian cancer SP cells express the
embryonic stem cell markers, NANOG, OCT4, STELLAR, and
ABCG2/BCRP1. OCT4 and NANOG are transcription factors in
embryonic stem cells (Nichols et al, 1998; Chambers et al, 2003;
Mitsui et al, 2003). Poorly differentiated tumours show over-
expression of genes that are normally enriched in embryonic stem
cells (Ben-Porath et al, 2008). NANOG and OCT4 are more
significantly overexpressed in poorly differentiated tumours than
in well-differentiated tumours (Ben-Porath et al, 2008). These
genes contribute to stem cell-like phenotypes found in many
tumours (Dvorak and Hampl, 2005; Wong et al, 2008). STELLAR,
also known as developmental pluripotency associated-3 (DPPA3),
is expressed in human embryonic cells. Particularly relevant is the
expression of ABCG2/BCRP1, a calcium-sensitive cell surface
protein that excludes Hoechst dye, conferring resistance to several
chemotherapeutic agents (Diestra et al, 2002b; Ahmed-Belkacem
et al, 2006). The ABCG2/BCRP1 gene was first isolated from
human tumour cell lines, in which it was involved in drug
resistance (Doyle et al, 1998; Allikmets et al, 1998b; Miyake et al,
1999). ABCG2/BCRP1 is a significant marker for Hoechst dye-
extruding stem cells (Zhou et al, 2001a). Various types of ABC
transporters, including proteins encoded by multidrug-resistance
gene 1 (MDR1, p-glycoprotein), multidrug resistance-associated
protein 1 (MRP1), as well as ABCG2/BCRP1, have been described.
In bone marrow from mdr1a1b
–/– knockout mice, a normal
percentage of SP cells was obtained, suggesting that MDR1 is not
correlated with the SP cells identified by Hoechst (Uchida et al,
2002). MDRI and MRP1 are not major contributors to the SP
phenotype in bone marrow cells (Scharenberg et al, 2002). MDR1
(CD44) is not a significant marker in the SP cells in our study.
However, several studies indicate that the presence of the ABCG2/
BCRP1 transporter is highly correlated with the SP phenotype in
various cells (Hirschmann-Jax et al, 2005) and is downregulated in
committed progenitor cells (Scharenberg et al, 2002; Zhou et al,
2002). Therefore, ABCG2/BCRP1 expression is a useful marker for
positive selection of several types of cancer stem-like cells (Kim
et al, 2002; Scharenberg et al, 2002; Patrawala et al, 2005; Ahmed-
Belkacem et al, 2006). In this study, we show that SP cells express
more ABCG2 than non-SP cells, supporting the concept that cancer
stem-like cells highly express ABCG2, as seen in other tumour
types (Patrawala et al, 2005; Abbott, 2006; Lou and Dean, 2007;
Olempska et al, 2007). Verapamil, an ABC transporter inhibitor
(Zhou et al, 2001a), which does not significantly inhibit the MDRI
transporter (Goodell, 2002), blocked SP cells from excluding the
Hoechst dye, indicating the important role of ABCG2/BRCP1 in the
SP of ovarian cancer cells. Our in vitro study of cisplatin-resistant
ovarian cancer cells (A2780-CR) indicates that SP cells are resistant
to chemotherapy and verapamil reverses this chemoresistance. The
results suggest that SP cells resist chemotherapy, at least partially
because of overexpression of ABCG2.
Stem cell markers NANOG and ABCG2/BCRP1 were colocalised
in both SP and non-SP cells, and the specific individual cells in
ovarian cancer tissues, as illustrated in our study, make it
reasonable to hypothesise that there are cancer stem-like cell
niches in ovarian cancer. The stem cell niche is in a specific
locale, within the structure in which the microenvironment
maintains the ‘stemness’ of stem cells (Fuchs and Segre, 2000).
The cancer stem-like cell niche may be important for maintaining
asymmetric divisions and stem-like properties (Iwasaki and Suda,
2009). Interaction with the cancer stem cell niche and tumour
microenvironment may lead to tumourigenesis (Howe et al, 1998;
Sternlicht et al, 1999).
In summary, we have shown that ovarian cancer cells are hetero-
genic. The SP cells have the characteristics of cancer stem-like
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Figure 5 Effect of cisplatin on tumour burden in mice inoculated i.p. with
SP vs non-SP isolated from A2780-CP cells. Treatments began 8 weeks
after inoculation. Treatment groups consisted of control (vehicle) and
cisplatin alone. At the end of the experiment (3 weeks of treatment), the
mice were killed. At autopsy, tumours were excised and weighed. SP-Con
(control)¼side population without treatment; SP-CP¼side population
with cisplatin treatment; NSP-Con¼non-side population without treat-
ment (control); NSP-CP¼non-side population with cisplatin treatment;
*Po0.05 vs NSP-CP; **Po0.01 vs SP-CON. Data are expressed as the
mean (bars±s.d.).
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scells. They are both highly tumourigenic and chemoresistant. The
increased expression of ABCG2/BCRP1 in SP cells is responsible
for chemoresistance. These observations have potentially impor-
tant implications for future therapeutic strategies that target the
ovarian cancer stem-like cells.
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